Corrigendum
The authors wish to make the following corrections to their article: Wan GJ, Chopra I, Niewoehner J, Hunter SF. Cost per response analysis of repository corticotropin injection versus other alternative treatments for acute exacerbations of multiple sclerosis. Drugs in Context 2020; 9: 2020-9-4. DOI: 10.7573/dic.2020-9-4
Original Research
The objective of this study was to estimate the cost per response of repository corticotropin injection compared with plasmapheresis or intravenous immunoglobulin from the United States commercial payer perspective.
Original Research
Schizophrenia is associated with high direct healthcare costs due to progression of disease and frequent occurrence of relapses. Aripiprazole once-monthly (AOM) has been shown to reduce total psychiatric hospitalizations among patients who switched from oral standard of care (SOC) therapy to AOM. In this paper the authors report the results of an economic model study to evaluate the psychiatric hospitalization-related medical costs and antipsychotic pharmacy costs during a 6-month period before and after initiation of AOM treatment.
